Biotechnology

During 2010 -2017 and during 2019-2024 approximately USD $150B and $198B respectively either have been and or are at risk of losing patent protection.

HCE is experienced and has developed a vast network to assist firms seeking to enter and maximize this unique opportunity for either new drug development, biosimilars, as well as bolt-on acquisitions.

HCE will assist innovator and or comparator firms seeking to expand their R & D efforts in developing biotechnology therapies with leading contract manufacturers utilizing state of the art processes such as continuous perfusion, rDNA and with the recent advent of rRNA within vaccine development that optimizes production offering significant advantages in downstream production leading to high quality efficacious products for end users.

HCE focuses upon but is not limited to certain disease states such as oncology, rheumatoid arthritis, nephrology, and hepatitis offering cutting edge products specifically colony stimulating factors (CSF) and monoclonal antibodies (mAB) to empower clients to enter this sector to meet unmet medical needs.

Pharmaceuticals

HCE will utilize its resources in a similar manner as that employed within the biotechnology segment.  In many instances pharmaceutical firms are seeking additional business opportunities within specified disease states in small molecules and or biologicals due to pipeline limitations.

Worldwide prescription drug sales are expected to grow at a CAGR of 6.9 percent to $842 billion during the 2019-2024 time period. This is triple the CAGR seen for 2010-2019 and is driven by an increase in FDA approvals for novel drugs and growth in the oncology therapies and orphan drugs markets.